Clinical Trials Logo

Bone Giant Cell Tumor clinical trials

View clinical trials related to Bone Giant Cell Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT03620149 Terminated - Clinical trials for Bone Giant Cell Tumor

Reduced Dose-density of Denosumab for Unresectable GCTB

REDUCE
Start date: September 26, 2019
Phase: Phase 2
Study type: Interventional

This study is a multi-center, multi-national, open label, single arm phase 2 study of single-agent denosumab. The objective of the trial is to evaluate the risk versus benefit of denosumab in maintenance setting in patients requiring long-term use (> 1 year) of denosumab. For that purpose, the treatment schedule with reduced dose density (120mg SC 12-weekly instead of 4-weekly) will be investigated, starting after 1-year (12-15 months) of denosumab full dose, as per current label. The impact on OsteoNecrosis of the Jaw (ONJ) without compromising disease control will be assessed.